Rapport Therapeutics partners with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China. $20M upfront + up to $308M milestones and tiered royalties for epilepsy & bipolar treatment.
uniQure stock jumps after Wells Fargo ($60 PT) and RBC ($35 PT) upgrades, driven by Vinay Prasad's FDA exit boosting AMT-130 Huntington's gene therapy outlook.
Xenon Pharmaceuticals reported strong Phase 3 results for azetukalner in focal onset seizures. The drug reduced monthly seizures by 53.2% vs 10.4% on placebo. NDA filing planned for Q3 2026.
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, its novel gene editing therapy designed to treat Duchenne muscular dystrophy (DMD).
Novo Nordisk is set to sell its popular weight-loss drugs like Wegovy on Hims & Hers platform soon, surprising many after a recent lawsuit over copycat versions. This could boost access and help both companies in the competitive obesity market.
Dr. Vinay Prasad, head of the FDA's vaccines and biologics division, is stepping down at the end of April after a controversial year overseeing approvals for vaccines, gene therapies, and biotech products.
